CD8A and neoplasm: Similar to the CD28/CTLA4 pathway, TIGIT/CD112 constitutes an emerging signaling pathway relating to the regulation of T cell immunity; indeed, a TIGIT blockade increases CD8+ T cell expansion against tumor antigens [102].